Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition of resistance genes via horizontal gene transfer. Resistance may develop de novo through mutation or be rapidly disseminated through mobile genetic elements like plasmids and transposons. Selection pressure from misuse and overuse of antibiotics accelerates the emergence and spread of resistant strains.
Clinically, antibiotic-resistant infections are harder to treat, often require more toxic or expensive drugs, prolong hospital stays, elevate healthcare costs, and increase morbidity and mortality. Global estimates warn of millions of deaths annually if resistance trends continue.
Methicillin‑Resistant Staphylococcus aureus (MRSA)
MRSA is a paradigm of antibiotic resistance. By acquiring the mecA gene through the SCCmec element, S. aureus produces the altered penicillin-binding protein PBP2a, which does not bind β‑lactam drugs, conferring broad resistance to penicillins, cephalosporins, and carbapenems . MRSA emerged in hospitals (HA‑MRSA) and later in communities (CA‑MRSA), driven by both mutation and horizontal gene transfer. Clinically, MRSA causes severe skin, soft‑tissue, bloodstream, and pneumonia infections, often treated with vancomycin, daptomycin, or linezolid, though these alternatives have limitations.
Some other examples of antibiotic resistance in bacteria:
Vancomycin‑Resistant Enterococci (VRE) and VRSA
Enterococci resistant to vancomycin emerged via acquisition of van gene operons (e.g., vanA). These genes have further transferred to S. aureus, resulting in rare but dangerous vancomycin-resistant S. aureus (VRSA) strains. VRSA infections are difficult to treat due to limited alternatives and are of grave clinical concern despite their rarity.
Drug‑Resistant Streptococcus pneumoniae (DRSP)
S. pneumoniae has developed resistance to penicillin through mutations in penicillin‑binding proteins and to macrolides via methyltransferase genes. These changes have reduced treatment efficacy for pneumonia, meningitis, and otitis media, necessitating higher‑tier antibiotics such as cephalosporins or fluoroquinolones, which carry their own risks .
In summary, antibiotic resistance evolves through genetic adaptation and gene exchange, with significant clinical impact across key pathogens like MRSA, VRE/VRSA, and DRSP. Ensuring appropriate antibiotic use, surveillance of resistance patterns, infection control, and development of novel therapeutics remain essential to mitigate this growing public health crisis.
Staphylococcus aureus is commonly found on human skin, but it is an opportunistic pathogen.
Methicillin-resistant Staphylococcus aureus, or MRSA, is a type of S. aureus resistant to methicillin and most other β-lactam antibiotics, like penicillin.
MRSA strains alter the penicillin-binding proteins, or PBPs, targeted by most β-lactams.
In MRSA strains, this resistance develops due to the presence of the mecA gene, which encodes an altered penicillin-binding protein known as PBP2a.
This altered PBP2a has a low binding affinity for beta-lactam antibiotics, allowing MRSA to synthesize its cell wall even in the presence of these drugs.
In many MRSA strains, the regulatory genes mecI and mecR1 controlling mecA expression are nonfunctional.
This results in the continuous expression of PBP2a and the development of stable resistance.
MRSA may exhibit heterogeneous resistance, where only a subset of the bacterial population expresses resistance, or homogeneous resistance, in which the entire population is resistant.
繁體中文
